Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences, Inc. - Common Stock (NQ:ENSC)

2.300 +0.050 (+2.22%)
Streaming Delayed Price Updated: 3:49 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ensysce Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Ensysce Biosciences, Inc. Announces Closing of $7 Million Public Offering
Via ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Ensysce Biosciences, Inc. Announces Pricing of $7 Million Public Offering
Via ACCESSWIRE
Why Is Ensysce Biosciences (ENSC) Stock Up 50% Today?
With Ensysce Biosciences achieving testing success regarding its overdose protection drug, ENSC stock soared on the implications. 
Via InvestorPlace
Ensysce Biosciences Announces Successful Completion of Ground-Breaking Study on Overdose Protection
Via ACCESSWIRE
Ensysce CEO Dr. Lynn Kirkpatrick To Present Featured Case Study of MPAR Overdose Protection Platform Accelerated Development
Via ACCESSWIRE
Ensysce Biosciences Announces Updated Investor Presentation Available Via Investor Relations Website
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease. 
Via Benzinga
Ensysce Biosciences's Return On Capital Employed Overview
 
Via Benzinga
Ensysce Biosciences Announces Positive Results from Oral Human Abuse Potential Trial for PF614
Via ACCESSWIRE
Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
Via ACCESSWIRE
Ensysce Biosciences (NASDAQ: ENSC) Successfully Completes Overdose-Protection Study
Ensysce Biosciences, Inc. (NASDAQ: ENSC) operates as a clinical-stage biotechnology company, which is focused on leveraging its proprietary technology to 
Via Spotlight Growth
Why Are Ensysce Biosciences Shares Are Trading Higher Today
Ensysce Biosciences Inc (NASDAQ: ENSC) completed PF614-MPAR-101, a clinical study examining the company's first pain medication with overdose protection,  
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Ensysce Biosciences, AST SpaceMobile, IGM Biosciences And Other Big Stocks Moving Lower On Friday
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Ensysce Biosciences Announces Completion of Enrollment for Groundbreaking Opioid Overdose Protection Study
Via ACCESSWIRE
Dr. Lynn Kirkpatrick, Featured Speaker to Discuss Ensysce Overdose Protection Platform at DCAT Seminar
Via ACCESSWIRE
Ensysce Biosciences Announces Critical Step in Human Abuse Potential Study of PF614 With Database Lock
Via ACCESSWIRE
Why Travelers Companies Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) gained 85.2% to $1.25 after the company announced the termination of its previously proposed registered direct offering. 
Via Benzinga
Ensysce Biosciences And 2 Other Stocks Under $2 Insiders Are Aggressively Buying
The Dow Jones rose around 40 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny... 
Via Benzinga
Ensysce Biosciences Provides Corporate Update
Via ACCESSWIRE
Stocks That Hit 52-Week Lows On Monday
  On Monday, 76 companies set new 52-week lows. 
Via Benzinga
ObsEva, Ensysce Biosciences And 2 Other Stocks Under $1 Insiders Are Aggressively Buying
The Dow Jones jumped by more than 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) climbed 49.9% to $4.93 after the company posted a profit for the fourth quarter. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday, 79 stocks hit new 52-week lows. 
Via Benzinga
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
Via ACCESSWIRE
Ensysce Biosciences to Present its Overdose Protection Program at the 4th Annual NIH 'HELPING END ADDICTION LONG-TERM' (HEAL) Meeting
Via ACCESSWIRE
Ensysce Biosciences, Inc. Announces Closing of $3.0 Million Registered Direct Offering Priced at-the-Market Under NASDAQ Rules
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.